| Title |
Canagliflozin: a novel treatment option for type 2 diabetes
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2013
|
| DOI | 10.2147/dddt.s48937 |
| Pubmed ID | |
| Authors |
Eric Dietrich, Jason Powell, James R Taylor |
| Abstract |
Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk-benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thereby increasing urinary glucose excretion. It reduces hemoglobin A1c by approximately 0.37%-1.16%; it also reduces the patient's weight and systolic blood pressure and has a low risk for hypoglycemia. Adverse effects include an increased risk of urinary tract infections and genital mycotic infections. In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 68 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 19% |
| Student > Bachelor | 10 | 14% |
| Researcher | 8 | 12% |
| Student > Ph. D. Student | 6 | 9% |
| Other | 5 | 7% |
| Other | 14 | 20% |
| Unknown | 13 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 41% |
| Agricultural and Biological Sciences | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Chemistry | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 17 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2018.
All research outputs
#7,959,659
of 25,371,288 outputs
Outputs from Drug Design, Development and Therapy
#543
of 2,268 outputs
Outputs of similar age
#69,617
of 226,635 outputs
Outputs of similar age from Drug Design, Development and Therapy
#13
of 40 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,635 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.